Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2023 07:25 ET | Source: Arch Biopartners

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

TORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has submitted a Clinical Trial Application to...
February 07, 2023 07:05 ET | Source: Arch Biopartners

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of...
November 15, 2021 09:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. Reports Third Quarter 2021 Financial Results

Quarterly revenues increased 38% to approximately $1.2 million, compared to approximately $0.8 million in the same quarter of the previous yearYear-to-date revenues increased 30% to $4.2 million,...
December 23, 2020 08:53 ET | Source: Arch Biopartners

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
November 05, 2020 08:04 ET | Source: Arch Biopartners

Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient dosing in Turkey has begun in the Phase...
November 30, 2017 06:00 ET | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS ANNOUNCES RESULTS FROM MECHANISM OF ACTION STUDY OF TOPICAL PH-10 FOR THE TREATMENT OF PSORIASIS

– Responses mediated by multiple pathways, including IL-17, IL-22 and interferons – – Down-regulation of more than 500 disease-related genes; wide range of central “psoriasis-related” genes...
September 29, 2017 08:00 ET | Source: Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering

Los Angeles, California, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...